CYAD Celyad Oncology SA Stock Quote

CYAD [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	2.39%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	4.56%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-2.46%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	23.12	Perf Half Y	-20.56%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-26.10%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	4.10 - 13.01	Perf YTD	7.24%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-35.70%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	104.02%	ATR	0.44
Employees	105	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.24	Volatility	2.98% 4.58%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.10	Prev Close	8.44
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	9.29K	Price	8.36
Recom	-	SMA20	2.91%	SMA50	-1.99%	SMA200	-11.15%	Volume	10,192	Change	-0.89%

Jul-05-19

Reiterated

H.C. Wainwright

Buy

$52 → $48

May-25-18

Initiated

Wells Fargo

Outperform

$44

Jan-11-21 04:01PM	Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors GlobeNewswire
Jan-07-21 01:00AM	Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital GlobeNewswire
Jan-05-21 01:00AM	Celyad Oncology Announces January 2021 Conference Schedule GlobeNewswire
Dec-15-20 04:01PM	Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC GlobeNewswire
Dec-07-20 01:00AM	Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition GlobeNewswire -10.09%
Dec-04-20 01:00AM	Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma GlobeNewswire
Dec-01-20 04:01PM	Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit GlobeNewswire
Nov-29-20 08:59AM	The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga
Nov-10-20 04:01PM	Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire +6.29%
Nov-04-20 04:01PM	Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition GlobeNewswire
Nov-02-20 04:01PM	Celyad Oncology Announces November 2020 Investor Conference Schedule GlobeNewswire +11.78%
Sep-29-20 05:53PM	Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer Zacks +6.51%
07:47AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut Benzinga
01:00AM	Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC GlobeNewswire
Sep-23-20 04:01PM	Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit GlobeNewswire
Sep-22-20 04:01PM	Celyad Oncology to Host Virtual Research & Development Webinar on September 29 GlobeNewswire
Sep-14-20 01:00AM	Celyad Oncology Establishes At-the-Market Facility GlobeNewswire
Aug-26-20 01:00AM	Celyad Oncology Announces September 2020 Conference Schedule GlobeNewswire
01:00AM	Celyad Oncology Announces September 2020 Conference Schedule Business Wire
Aug-06-20 04:01PM	Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights GlobeNewswire
Aug-03-20 01:00AM	Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call GlobeNewswire
01:00AM	Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call Business Wire
Jul-15-20 10:34AM	Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate Zacks
Jul-14-20 01:00AM	Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy GlobeNewswire +11.39%
01:00AM	Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy Business Wire
Jun-10-20 01:00AM	Celyad Rebrands as Celyad Oncology GlobeNewswire +5.18%
Jun-01-20 01:00AM	Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program GlobeNewswire +10.01%
May-27-20 09:34AM	5 Health Care Stocks to Bet on as Coronavirus Woes Linger Zacks +7.54%
May-26-20 01:00AM	Celyad Announces June 2020 Conference Schedule GlobeNewswire +8.54%
May-25-20 12:00PM	All You Need to Know About Celyad SA (CYAD) Rating Upgrade to Strong Buy Zacks
May-24-20 07:00AM	3 Strong Buy Healthcare Stocks That Could Double in the Next Year TipRanks
May-07-20 01:00AM	Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire +6.41%
May-06-20 01:00AM	Celyad Appoints Seasoned Industry Executives to Board of Directors GlobeNewswire
Apr-30-20 01:00AM	Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program GlobeNewswire
Apr-22-20 01:00AM	Celyad to Host Remote 2020 Ordinary General Meeting GlobeNewswire
Apr-20-20 09:06AM	Top Ranked Momentum Stocks to Buy for April 20th Zacks +6.21%
Mar-31-20 12:00PM	What Makes Celyad SA (CYAD) a New Buy Stock Zacks -7.93%
Mar-26-20 04:42AM	Imagine Owning Celyad (EBR:CYAD) And Trying To Stomach The 84% Share Price Drop Simply Wall St.
Mar-25-20 11:00AM	Celyad SA to Host Earnings Call ACCESSWIRE +39.37%
Mar-24-20 07:36PM	Celyad Reports Full Year 2019 Financial Results and Provides Business Update Business Wire +14.12%
Mar-12-20 04:01PM	Celyad to Announce Full Year 2019 Financial Results and Host Conference Call GlobeNewswire -19.53%
Mar-02-20 01:00AM	Celyad Appoints Stephen Rubino as Chief Business Officer GlobeNewswire +8.82%
Feb-17-20 01:00AM	Celyad Announces February and March 2020 Conference Schedule GlobeNewswire
Jan-13-20 01:00AM	Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS GlobeNewswire +7.93%
Dec-10-19 03:21AM	Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting Business Wire -12.92%
Dec-09-19 06:30PM	Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting GlobeNewswire -5.36%
Dec-07-19 08:35AM	The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 01:33AM	Celyad Receives Additional 2.5 Million in Non-Dilutive Funding Business Wire +5.05%
01:00AM	Celyad Receives Additional 2.5 Million in Non-Dilutive Funding GlobeNewswire
Dec-03-19 07:05AM	Celyad Announces Board of Directors Evolution with New Appointment Business Wire +6.30%
Nov-29-19 01:00AM	Celyad Announces Board of Directors Evolution with New Appointment GlobeNewswire
Nov-22-19 08:18AM	The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga +10.27%
01:00AM	Celyad Receives 8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region GlobeNewswire
Nov-19-19 01:00AM	Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire +20.02%
01:00AM	Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights Business Wire
Nov-13-19 09:00AM	Celyad SA (CYAD) Moves to Buy: Rationale Behind the Upgrade Zacks
Nov-11-19 01:00AM	Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting GlobeNewswire
Nov-06-19 09:00AM	Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting GlobeNewswire
Nov-05-19 08:00AM	Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting GlobeNewswire -9.37%
08:00AM	Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting Business Wire
Nov-03-19 10:51AM	The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga
Oct-22-19 12:34AM	Does Celyad SA (EBR:CYAD) Have A Volatile Share Price? Simply Wall St. -9.19%
Oct-02-19 01:00AM	Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting GlobeNewswire
01:00AM	Celyad Announces October and November 2019 Investor Conference Schedule GlobeNewswire
Sep-16-19 04:01PM	Celyad Announces Closing of $20 Million Global Offering GlobeNewswire
Sep-12-19 09:56AM	Celyad Announces Pricing of $20.0 Million Global Offering Business Wire -22.12%
09:28AM	Celyad Announces Pricing of $20.0 Million Global Offering GlobeNewswire
Sep-11-19 07:09AM	The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway Benzinga
Sep-10-19 04:01PM	Celyad Announces Launch of Proposed Global Offering GlobeNewswire
Sep-04-19 02:42AM	Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process Business Wire +9.17%
01:00AM	Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process GlobeNewswire
Aug-29-19 01:00AM	Celyad to Participate in Upcoming September 2019 Conferences GlobeNewswire
Aug-22-19 04:00PM	Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights GlobeNewswire
01:20AM	Some Celyad (EBR:CYAD) Shareholders Have Taken A Painful 71% Share Price Drop Simply Wall St.
Aug-16-19 01:00AM	Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call GlobeNewswire +7.07%
Jul-15-19 09:17AM	Celyad Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-05-19 08:55AM	The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight Benzinga
03:21AM	Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors GlobeNewswire
Jul-02-19 04:01PM	Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress GlobeNewswire +9.83%
07:29AM	The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
Jul-01-19 04:01PM	Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program GlobeNewswire
Jun-21-19 08:45AM	Celyad SA Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-17-19 04:32PM	Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association GlobeNewswire -28.04%
Jun-03-19 06:48AM	Celyad Sees Hammer Chart Pattern: Time to Buy? Zacks
May-29-19 01:00AM	Celyad to Participate in Upcoming June 2019 Conferences GlobeNewswire
May-16-19 04:01PM	Celyad to Present Data at 24th Congress of the European Hematology Association GlobeNewswire
May-09-19 01:00AM	Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
May-02-19 04:01PM	Celyad Announces May 2019 Investor Conference Schedule GlobeNewswire
Apr-17-19 04:01PM	Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress GlobeNewswire
Apr-01-19 04:01PM	Celyad Announces April 2019 Investor Conference Schedule GlobeNewswire +7.60%
Mar-28-19 04:05PM	Celyad Reports Business Update and Full Year 2018 Financial and Operating Results GlobeNewswire
04:01PM	Celyad Appoints Filippo Petti as Chief Executive Officer GlobeNewswire
Mar-18-19 04:01PM	Celyads 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates GlobeNewswire
Mar-11-19 02:00AM	Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City GlobeNewswire
Mar-08-19 01:00AM	Celyad Appoints Anne Moore as Vice President Corporate Strategy GlobeNewswire
Feb-21-19 04:01PM	Celyad Announces February and March 2019 Investor Conference Schedule GlobeNewswire
Jan-07-19 01:00AM	Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS GlobeNewswire +7.22%
Dec-04-18 01:45AM	Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting GlobeNewswire -7.44%
Nov-30-18 08:25AM	The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
01:00AM	Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101 GlobeNewswire

Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience